New strategy tested for lung cancer that outsmarts first treatment
NCT ID NCT06652048
Summary
This study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has started growing again after their first targeted treatment. Researchers want to see if giving a higher dose of the drug furmonertinib, or combining a standard dose with chemotherapy, can better control the cancer. The study will enroll 60 participants to compare these different approaches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university shanghai cancer center
RECRUITINGShanghai, Shanghai Municipality, 021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.